Latest Breaking News On - Lentigen technology - Page 1 : comparemela.com

Arovella Therapeutics well-placed to advance iNKT cell therapy cancer treatment towards first-in-human clinical trials

Arovella Therapeutics well-placed to advance iNKT cell therapy cancer treatment towards first-in-human clinical trials
proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.

Tim luscombeArovella therapeutics ltdLentigen technology incSparx groupProactive australiaLentigen technologyInvestigational new drug

Arovella Therapeutics takes key manufacturing step on ALA-101 s path to clinic

Arovella Therapeutics takes key manufacturing step on ALA-101 s path to clinic
proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomMichael bakerLentigen technology incArovella therapeutics ltdSparx groupImperial college londonGood manufacturing practiceLentigen technologyChimeric antigen receptor

Vector BioMed Appoints Jakob Reiser, Ph D , as Senior Director of Regulatory Affairs

/PRNewswire/ Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced the appointment of Jakob.

United statesNew orleansMike kadanDave schemeliaBoro dropuliAndrew wordenJakob reiserMiltenyi biotecDaniel kontoh boatengRegulatory affairsHealth sciences centerGenetic therapy incDrug administrationLentigen technologyRegulatory affairs at vector biomedLouisiana state university

Is bluebird bio s Surge a Bellwether for Gene Editing Stocks?

Is bluebird bio s Surge a Bellwether for Gene Editing Stocks?
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.

United statesNovarti zolgensmaCenters for diseaseDrug administrationThermofisher scientific or lentigen technologyEuropean medicines agencyBristol myers squibbDisease controlThermofisher scientificLentigen technologyஒன்றுபட்டது மாநிலங்களில்மையங்கள் க்கு நோய்பிரிஸ்டல் மைஸ் ஸ்க்விப்ப்நோய் கட்டுப்பாடு

Oncternal Therapeutics, Inc (ONCT) Q1 2021 Earnings Call Transcript

Operator Good day ladies and gentlemen and welcome to Oncternal s Therapeutics Inc. first-quarter 2021 financial results call. [Operator instructions] At this time it is my pleasure to turn the floor over to your host Richard Vincent. Sir the floor is yours. Rich Vincent Chief Financial Officer Thank you, Melinda. Good afternoon, everyone, and thank you for joining us today. Joining me on the call this afternoon are our president and CEO, Dr. James Breitmeyer; and our acting CMO, Dr. Edwina Baskin-Bey. We welcome all of you. Today s call includes a business update and discussion of our 2021 first-quarter financial results which will be followed by Q&A. Today s press release and replay of today s earnings call will be available on the Investor Relations section of Oncternal s website for at least the next 30 days.

United statesSan diegoKumar rajaCarl byrnesJames breitmeyerHartaj singhRobert burnsEdwina baskin beyJim breitmeyerKumar raja brooklineRichard vincentCarl byrnes northlandKarolinska instituteAmerican society for clinical oncologyBoehringer ingelheimOppenheimer co